Adolescent vaccination with BNT162b2 (Comirnaty, Pfizer-BioNTech) vaccine and effectiveness of the first dose against COVID-19: national test-negative case-control study, England
Annabel A Powell, Freja Kirsebom, Julia Stowe, Kelsey McOwat, Vanessa Saliba, Mary E Ramsay, Jamie Lopez-Bernal, Nick Andrews, Shamez N Ladhani
doi: https://doi.org/10.1101/2021.12.10.21267408
Annabel A Powell
1UK Health Security Agency, London, United Kingdom
Freja Kirsebom
1UK Health Security Agency, London, United Kingdom
Julia Stowe
1UK Health Security Agency, London, United Kingdom
Kelsey McOwat
1UK Health Security Agency, London, United Kingdom
Vanessa Saliba
1UK Health Security Agency, London, United Kingdom
Mary E Ramsay
1UK Health Security Agency, London, United Kingdom
2NIHR Health Protection Research Unit in Vaccines and Immunisation, London School of Hygiene and Tropical Medicine, London, United Kingdom
Jamie Lopez-Bernal
1UK Health Security Agency, London, United Kingdom
2NIHR Health Protection Research Unit in Vaccines and Immunisation, London School of Hygiene and Tropical Medicine, London, United Kingdom
3NIHR Health Protection Research Unit in Respiratory Infections, Imperial College London, London, United Kingdom
Nick Andrews
1UK Health Security Agency, London, United Kingdom
2NIHR Health Protection Research Unit in Vaccines and Immunisation, London School of Hygiene and Tropical Medicine, London, United Kingdom
Shamez N Ladhani
1UK Health Security Agency, London, United Kingdom
4Paediatric Infectious Diseases Research Group, St George’s University of London, London, UK
Posted December 11, 2021.
Adolescent vaccination with BNT162b2 (Comirnaty, Pfizer-BioNTech) vaccine and effectiveness of the first dose against COVID-19: national test-negative case-control study, England
Annabel A Powell, Freja Kirsebom, Julia Stowe, Kelsey McOwat, Vanessa Saliba, Mary E Ramsay, Jamie Lopez-Bernal, Nick Andrews, Shamez N Ladhani
medRxiv 2021.12.10.21267408; doi: https://doi.org/10.1101/2021.12.10.21267408
Adolescent vaccination with BNT162b2 (Comirnaty, Pfizer-BioNTech) vaccine and effectiveness of the first dose against COVID-19: national test-negative case-control study, England
Annabel A Powell, Freja Kirsebom, Julia Stowe, Kelsey McOwat, Vanessa Saliba, Mary E Ramsay, Jamie Lopez-Bernal, Nick Andrews, Shamez N Ladhani
medRxiv 2021.12.10.21267408; doi: https://doi.org/10.1101/2021.12.10.21267408
Subject Area
Subject Areas
- Addiction Medicine (386)
- Allergy and Immunology (701)
- Anesthesia (193)
- Cardiovascular Medicine (2859)
- Dermatology (244)
- Emergency Medicine (431)
- Epidemiology (12569)
- Forensic Medicine (10)
- Gastroenterology (807)
- Genetic and Genomic Medicine (4447)
- Geriatric Medicine (402)
- Health Economics (716)
- Health Informatics (2856)
- Health Policy (1050)
- Hematology (376)
- HIV/AIDS (893)
- Medical Education (415)
- Medical Ethics (114)
- Nephrology (464)
- Neurology (4201)
- Nursing (223)
- Nutrition (617)
- Oncology (2205)
- Ophthalmology (626)
- Orthopedics (254)
- Otolaryngology (319)
- Pain Medicine (269)
- Palliative Medicine (83)
- Pathology (488)
- Pediatrics (1172)
- Primary Care Research (483)
- Public and Global Health (6787)
- Radiology and Imaging (1494)
- Respiratory Medicine (902)
- Rheumatology (430)
- Sports Medicine (369)
- Surgery (473)
- Toxicology (57)
- Transplantation (202)
- Urology (174)